TOP TEN perturbations for 39565_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39565_at
Selected probe(set): 204832_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39565_at (204832_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-2.7923603Number of Samples:2 / 2
Experimental | zalypsis study 2 |
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
Control | untreated OPM1 cell sample |
OPM1 multiple myeloma cells untreated. |
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-2.6612453Number of Samples:3 / 3
Experimental | echinomycin study 1 |
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
Control | deferoxamine study 5 |
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):2.4188204Number of Samples:2 / 4
Experimental | glioma study 17 ( small cell glioblastoma; unsorted) |
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males. | |
Control | non-tumor cortical tissue |
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
T-cell isolation study 11 / T-cell isolation study 6
Relative Expression (log2-ratio):-2.4153433Number of Samples:2 / 2
Experimental | T-cell isolation study 11 |
CD4+ resting memory T-cell were isolated from peripheral blood buffy coat of healthy donors after storage for 24 hours at 20°C. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population. | |
Control | T-cell isolation study 6 |
CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population. |
glioma study 27 (glioblastoma, NOS) / glioma study 27 (pilocytic astrocytoma)
Relative Expression (log2-ratio):2.2998161Number of Samples:4 / 2
Experimental | glioma study 27 (glioblastoma, NOS) |
Primary tumor samples from resected brain tissues of patients with glioblastoma, NOS(WHO grade IV astrocytoma). | |
Control | glioma study 27 (pilocytic astrocytoma) |
Primary tumor samples from resected brain tissues of patients with pilocytic astrocytoma (WHO grade I astrocytoma). |
plicamycin study 1 (100 nM) / vehicle (PBS) treated TC-32 cell sample
Relative Expression (log2-ratio):-2.2659683Number of Samples:3 / 3
Experimental | plicamycin study 1 (100 nM) |
TC-32 Ewing's sarcoma cells treated with compound: plicamycin (mithramycin, 100 nM) for 6 hours. ATC code: | |
Control | vehicle (PBS) treated TC-32 cell sample |
TC-32 Ewing's sarcoma cells treated with 0.01% phosphate-buffered saline (PBS) in growth medium for 6 hours. |
Merkel cell carcinoma study 3 (primary) / basal cell carcinoma study 2
Relative Expression (log2-ratio):-2.192068Number of Samples:19 / 2
Experimental | Merkel cell carcinoma study 3 (primary) |
Primary tumor tissue from the skin of patients with Merkel cell carcinoma. | |
Control | basal cell carcinoma study 2 |
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC). |
influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.0835857Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/pH1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-2.0716228Number of Samples:2 / 2
Experimental | bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted). | |
Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)
Relative Expression (log2-ratio):2.045268Number of Samples:3 / 3
Experimental | influenza virus study 9 (A/H9N2) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection. | |
Control | influenza virus study 4 (A/H1N1) |
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection. |
Organism: Homo sapiens
Gene: 39565_at
Selected probe(set): 213578_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39565_at (213578_at) across 6674 perturbations tested by GENEVESTIGATOR:
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-3.741211Number of Samples:2 / 4
Experimental | R547 study 1 (24h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):-3.6838665Number of Samples:2 / 2
Experimental | zalypsis study 2 |
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
Control | untreated OPM1 cell sample |
OPM1 multiple myeloma cells untreated. |
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-3.6531153Number of Samples:3 / 3
Experimental | echinomycin study 1 |
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
Control | deferoxamine study 5 |
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
CAR T cell study 4 (PSCA-28t28Z; pre-infusion) / CAR T cell study 4 (GFP; pre-infusion)
Relative Expression (log2-ratio):-2.9502516Number of Samples:3 / 3
Experimental | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). | |
Control | CAR T cell study 4 (GFP; pre-infusion) |
Primary human CD8+ T cells stimulated ex vivo and transduced to express GFP. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding GFP as a control. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
R547 study 3 (6h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-2.782668Number of Samples:4 / 4
Experimental | R547 study 3 (6h) |
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 6 hours at an IC90 concentration of IC90 = 1.7 μmol/L. ATC code:--- | |
Control | vehicle (DMSO) treated DU145 cell sample |
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 6 hours. |
oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample
Relative Expression (log2-ratio):-2.5201244Number of Samples:3 / 3
Experimental | oncolytic herpes simplex virus study 2 |
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours. | |
Control | mock infected peripheral nerve sheath tumor (S462) cell sample |
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours. |
Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample
Relative Expression (log2-ratio):2.4765272Number of Samples:7 / 3
Experimental | Langerhans cell histiocytosis study 1 |
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
Control | normal plasmocytoid dendritic cell sample |
Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population. |
T-helper activation study 1 (240min) / unstimulated helper T-cell sample
Relative Expression (log2-ratio):-2.4180002Number of Samples:2 / 2
Experimental | T-helper activation study 1 (240min) |
Alloantigen specific helper T-cells were stimulated for 240min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors. | |
Control | unstimulated helper T-cell sample |
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors. |
plicamycin study 1 (100 nM) / vehicle (PBS) treated TC-32 cell sample
Relative Expression (log2-ratio):-2.3761368Number of Samples:3 / 3
Experimental | plicamycin study 1 (100 nM) |
TC-32 Ewing's sarcoma cells treated with compound: plicamycin (mithramycin, 100 nM) for 6 hours. ATC code: | |
Control | vehicle (PBS) treated TC-32 cell sample |
TC-32 Ewing's sarcoma cells treated with 0.01% phosphate-buffered saline (PBS) in growth medium for 6 hours. |
CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Relative Expression (log2-ratio):2.3752384Number of Samples:3 / 3
Experimental | CAR T cell study 4 (PSCA-28t28Z; post-infusion) |
CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
Control | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |